BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23456571)

  • 21. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer.
    Wang YF; Feng FL; Zhao XH; Ye ZX; Zeng HP; Li Z; Jiang XQ; Peng ZH
    World J Gastroenterol; 2014 Apr; 20(14):4085-92. PubMed ID: 24744600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242.
    Björkman K; Mustonen H; Kaprio T; Kekki H; Pettersson K; Haglund C; Böckelman C
    Tumour Biol; 2021; 43(1):57-70. PubMed ID: 33935125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.
    Nilsson O; Johansson C; Glimelius B; Persson B; Nørgaard-Pedersen B; Andrén-Sandberg A; Lindholm L
    Br J Cancer; 1992 Feb; 65(2):215-21. PubMed ID: 1739620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
    Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
    Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer.
    Xu X; Xiao Y; Hong B; Hao B; Qian Y
    Cancer Biomark; 2019; 25(3):251-257. PubMed ID: 31282407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].
    Zhu YB; Ge SH; Zhang LH; Wang XH; Xing XF; DU H; Hu Y; Li YA; Jia YN; Lin Y; Fan B; Ji JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):161-4. PubMed ID: 22368025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer.
    Liu F; Du F; Chen X
    World J Surg Oncol; 2014 Nov; 12():333. PubMed ID: 25381564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
    Huang C; Bei L; Liu T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of CA242 and CA19-9 in chronic pancreatitis.
    Furuya N; Kawa S; Hasebe O; Tokoo M; Mukawa K; Maejima S; Oguchi H
    Br J Cancer; 1996 Feb; 73(3):372-6. PubMed ID: 8562344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
    Liang B; Zhong L; He Q; Wang S; Pan Z; Wang T; Zhao Y
    Med Sci Monit; 2015 Nov; 21():3555-63. PubMed ID: 26576628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of the Diagnostic Performance of Circulating MicroRNAs for Pancreatic Cancer.
    Peng C; Wang J; Gao W; Huang L; Liu Y; Li X; Li Z; Yu X
    Int J Med Sci; 2021; 18(3):660-671. PubMed ID: 33437201
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
    Satake K; Takeuchi T
    Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.
    Chen Y; Gao SG; Chen JM; Wang GP; Wang ZF; Zhou B; Jin CH; Yang YT; Feng XS
    Cell Biochem Biophys; 2015 Apr; 71(3):1287-91. PubMed ID: 25486903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis.
    Kumar Y; Gurusamy K; Pamecha V; Davidson BR
    Pancreas; 2007 Aug; 35(2):114-9. PubMed ID: 17632316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CA242 as a biomarker for pancreatic cancer and other diseases.
    Dou H; Sun G; Zhang L
    Prog Mol Biol Transl Sci; 2019; 162():229-239. PubMed ID: 30905452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
    Joergensen MT; Brünner N; De Muckadell OB
    Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer.
    Fujimoto Y; Suehiro Y; Kaino S; Suenaga S; Tsuyama T; Matsui H; Higaki S; Fujii I; Suzuki C; Hoshida T; Matsumoto T; Takami T; Nagano H; Sakaida I; Yamasaki T
    Oncology; 2021; 99(4):234-239. PubMed ID: 33440396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.